Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of <sup>18</sup>F-DCFPyL PET/CT with Comparison to Multiparametric MRI

Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of <sup>18</sup>F-DCFPyL PET/CT with Comparison to Multiparametric MRI

Background Prostate cancer recurrence is found in up to 40% of men with prior definitive (total prostatectomy or whole-prostate radiation) treatment. Prostate-specific membrane antigen PET agents such as 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid...

Whakaahuatanga katoa

I tiakina i:
Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua: Liza Lindenberg, Esther Mena, Barış Türkbey, Joanna H. Shih, Sarah E. Reese, Stephanie A. Harmon, Ilhan Lim, Frank I. Lin, Anita Ton, Yolanda McKinney, Philip Eclarinal, Deborah E. Citrin, William L. Dahut, Ravi A. Madan, Bradford J. Wood, Venkatesh Krishnasamy, Richard Chang, Elliot Levy, Peter A. Pinto, Janet F. Eary, Peter L. Choyke
Hōputu: Artigo
Reo:Ingarihi
I whakaputaina: 2020
Urunga tuihono:https://doi.org/10.1148/radiol.2020192018
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
Me noho koe te mea tuatahi ki te waiho tākupu!
Me takiuru i te tuatahi

Ngā tūemi rite